AGP Executive Report
Last update: 7 hours agoMedicines: Strong European sales of the antifungal Cresemba triggered a $37.5 million milestone payment to Swiss drugmaker Basilea. The medicine is approved in Liechtenstein for certain invasive fungal infections. Drug Safety: The European Medicines Agency is reviewing depression and anxiety medicine Deanxit after reports of movement problems and memory or thinking difficulties, sometimes continuing after treatment stops. Reproductive Health: Liechtenstein’s Prince Alois has vetoed a bill that would have allowed abortion during the first 12 weeks of pregnancy, leaving the country’s existing restrictions in place.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.